Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
ginsenoside m 5/mŕtvica
Odkaz sa uloží do schránky
Strana 1 od 89 výsledky
Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Ginsenoside Rd (Rd), one of the main active ingredients in Panax ginseng, has been demonstrated to protect against ischemic cerebral damage in vitro and in vivo. In this study, we aimed to further define the preclinical characteristics of Rd. We show that Rd passes the intact blood-brain barrier and
Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
We previously found that ginsenoside Rd (Rd), one of the main active ingredients in Panax ginseng, protects against ischemic brain damage induced by oxygen-glucose deprivation in vitro and middle cerebral artery occlusion (MCAO) in vivo. Considering stroke happens frequently in aged individuals, we
Ginsenoside-Rd, a new voltage-independent Ca2+ entry blocker, reverses basilar hypertrophic remodeling in stroke-prone renovascular hypertensive rats.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The total saponins of Panax notoginseng have been clinically used for the treatment of cardiovascular diseases and stroke in China. Our recent study has identified ginsenoside-Rd, a purified component of total saponins of P. notoginseng, as an inhibitor to remarkably inhibit voltage-independent
Ginsenoside-Rd improves outcome of acute ischaemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
Ginsenoside-Rd is a receptor-operated calcium channel antagonist and has shown promise as a neuroprotectant in our phase II study. As an extended work, we sought to confirm its efficacy and safety of Ginsenoside-Rd in patients with acute ischaemic stroke.
METHODS
We conducted a randomized,
Ginsenoside Rb1 reduces neurodegeneration in the peri-infarct area of a thromboembolic stroke model in non-human primates.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Ginsenoside Rb1 (GRb1), a major component of the traditional herb ginseng, has been reported to show a neuroprotective effect in a rodent ischemic model. The purpose of this study was to investigate effects of GRb1 on early and delayed brain injuries in a non-human primate thromboembolic stroke
Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Numerous studies have identified pathophysiological mechanisms of acute ischemic stroke and have provided proof-of-principle evidence that strategies designed to impede the ischemic cascade, namely neuroprotection, can protect the ischemic brain. However, the translation of these therapeutic agents
Ginsenoside-Rb1 for Ischemic Stroke: A Systematic Review and Meta-analysis of Preclinical Evidence and Possible Mechanisms.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
A great deal of attention has been paid to neuroprotective therapies for cerebral ischemic stroke. Our two recent clinical trials showed that ginsenoside Rd (Rd), a kind of monomeric compound extracted from Chinese herbs, Panax ginseng and Panax notoginseng, was safe and efficacious for the
A systematic review and meta-analysis of Ginsenoside-Rg1 (G-Rg1) in experimental ischemic stroke.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The neuroprotective actions of Ginsenoside-Rg1 (G-Rg1) have been documented for experimental stroke therapy. We used a systematic review and meta-analysis to assess the efficacy of G-Rg1 in experimental ischemic stroke. We identified studies describing the efficacy of G-Rg1 in animal models of focal
Ginsenoside Rd and ischemic stroke; a short review of literatures.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Panax ginseng is a well-known economic medical plant that is widely used in Chinese traditional medicine. This species contains a unique class of natural products-ginsenosides. Recent clinical and experimental studies have presented numerous lines of evidence on the promising role of ginsenosides on
Ginsenoside Rb1 Promotes Motor Functional Recovery and Axonal Regeneration in Post-stroke Mice through cAMP/PKA/CREB Signaling Pathway.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The central nervous system (CNS) has a poor self-repairing capability after injury because of the inhibition of axonal regeneration by many myelin-associated inhibitory factors. Therefore, ischemic stroke usually leads to disability. Previous studies reported that Ginsenoside Rb1 (GRb1) plays a role
Metabolomic Profiling of the Synergistic Effects of Ginsenoside Rg1 in Combination with Neural Stem Cell Transplantation in Ischemic Stroke Rats.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
As the greatest medical and socioeconomic problem in developing countries, stroke is the second or third leading cause of death in China and worldwide. In adult organisms suffering from stroke, transplanted stem cell has the ability to repair damaged tissues by regenerating autologous cells, while
Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
Ginsenoside-Rd is a selective competitive Ca2+ receptor antagonist. A phase II randomized, double-blind, placebo-controlled, multicenter study was conducted to examine the efficacy and safety of ginsenoside-Rd in patients with acute ischaemic stroke.
METHODS
A total of 199 patients were
Ginsenoside F1 promotes angiogenesis by activating the IGF-1/IGF1R pathway.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Ischemic stroke is one of the most lethal and highly disabling diseases that seriously affects the human health and quality of life. A therapeutic angiogenic strategy has been proposed to alleviate ischemia-induced injury by promoting angiogenesis and improving cerebrovascular function in the
Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-κB nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Our previous clinical and basic studies have demonstrated that ginsenoside Rd (GS-Rd) has remarkable neuroprotective effects after cerebral ischemia but the underlying mechanisms are still unknown. In our latest studies, we revealed that GS-Rd could prevent mitochondrial release of
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
